Lynch Syndrome in Urologic Malignancies – What Does the Urologist Need to Know?

Hanan Goldberg, Christopher J.D. Wallis, Zachary Klaassen, Thenappan Chandrasekar, Neil Fleshner, Alexandre R. Zlotta

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Lynch Syndrome (LS) entails a defective DNA mismatch repair system, which is the postreplicative proofreading and editing system, ensuring our genome's integrity. LS predisposes to several cancers, most commonly colorectal and endometrial cancers. LS occurs in approximately 1 in 250–1000 people. LS is associated with urological malignancies with upper tract urothelial carcinoma the most common, although still clinically underestimated. Other urologic malignancies possibly associated with LS include bladder, prostate, testis, and renal cell carcinoma. Ascertaining their true prevalence in LS is mandatory for their and their relatives’ diagnosis and treatment. Awareness regarding identifying patients at risk for LS through assessment of personal and familial oncologic history is critical among urologists.

Original languageEnglish (US)
Pages (from-to)24-31
Number of pages8
StatePublished - Dec 2019
Externally publishedYes

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Lynch Syndrome in Urologic Malignancies – What Does the Urologist Need to Know?'. Together they form a unique fingerprint.

Cite this